<DOC>
	<DOC>NCT00111813</DOC>
	<brief_summary>The purposes of this study are: - To determine the maximum tolerated dose (MTD) for the combination of oral vorinostat and bortezomib in participants with advanced multiple myeloma - To assess the safety and tolerability of this regimen and to document the participant's clinical status (by anti-tumor activity) for this combination, as determined per standard of care.</brief_summary>
	<brief_title>Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Adults with refractory or relapsed multiple myeloma Eastern Cooperative Oncology Group (ECOG) performance status of 02 (a measurement to determine participant's ability to perform daily activities) Adequate bone marrow reserve Adequate hepatic and renal function Ability to swallow capsules 3 weeks or more since prior chemotherapy and have recovered from prior toxicities Participants who plan to have a bone marrow transplant within 4 weeks of start of treatment Participants with prior treatment with other investigational agents with a similar antitumor mechanism Participants with other active/uncontrolled clinically significant illness Pregnant or nursing female participants Participants who received bortezomib within 3 months of start of this trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>